Comparison of Difference Hydrodissection for CTS

Sponsor
Tri-Service General Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT03031041
Collaborator
(none)
47
1
2
31.1
1.5

Study Details

Study Description

Brief Summary

Carpal tunnel syndrome (CTS) is the most common peripheral entrapment neuropathy with involving compression of the median nerve in the carpal tunnel. Rather than other progressive disease, CTS is characterized by remission and recurrence. The hydrodissection could decrease the entrapment of nerve to restore blood supply. Despite the hydrodissection was pervasively used in clinical practice, current researches contain small participant without control group or randomized leading to foreseeable selection bias. The investigators design a randomized, double-blind, controlled trial to assess the effect of different method of ultrasound-guided hydrodissection in patients with CTS.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Ultrasound-guided short-axis hydrodissection with 5cc normal saline
  • Procedure: Ultrasound-guided long-axis hydrodissection with 3cc normal saline
N/A

Detailed Description

After obtaining written informed consent, patients with bilateral CTS will been randomized into intervention and control group. Participants in short-axis group received one-dose ultrasound-guided hydrodissection with short-axis approach and long-axis group received one-dose ultrasound-guided injection with long-axis approach. No additional treatment after injection through the study period. The primary outcome is Boston Carpal Tunnel Syndrome Questionnaire (BCTQ) and secondary outcomes include visual analog scale (VAS), cross-sectional area (CSA) of the median nerve, sensory nerve conduction velocity of the median nerve, and finger pinch strength. The evaluation was performed pretreatment as well as on the 2nd week, 1st, 2nd, 3rd and 6th month after the treatment.

Study Design

Study Type:
Interventional
Actual Enrollment :
47 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
Comparison of Difference Hydrodissection Technique in Patients With Carpal Tunnel Syndrome
Actual Study Start Date :
Jan 25, 2017
Actual Primary Completion Date :
Aug 30, 2019
Actual Study Completion Date :
Aug 30, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: Short-axis hydrodissection

Ultrasound-guided short-axis hydrodissection with normal saline between carpal tunnel and median nerve

Procedure: Ultrasound-guided short-axis hydrodissection with 5cc normal saline
Ultrasound-guided short-axis hydrodissection with 5cc normal saline between carpal tunnel and median nerve

Active Comparator: Long-axis hydrodissection

Ultrasound-guided long-axis hydrodissection with normal saline between carpal tunnel and median nerve

Procedure: Ultrasound-guided long-axis hydrodissection with 3cc normal saline
Ultrasound-guided long-axis hydrodissection with 3cc normal saline between carpal tunnel and median nerve

Outcome Measures

Primary Outcome Measures

  1. Change from baseline of severity of symptoms and functional status on 2nd week, 1st, 2nd, 3rd and 6th month after injection [Pre-treatment, 2nd week, 1st, 2nd, 3rd and 6th month after injection]

    Boston carpal tunnel syndrome questionnaire (BCTQ) is a frequently used patient-based questionnaire for measurement of CTS which encompasses two components. In total, 11 questions and 8 items were evaluated to rate the symptom severity scale (SSS) and functional status scale (FSS), respectively. Both subscales range from 1 to 5 with a higher score indicating a higher degree of disability. The mean of total SSS and FSS divided with each item score were used for further analysis.

Secondary Outcome Measures

  1. Change from baseline of pain on 2nd week, 1st, 2nd, 3rd and 6th month after injection [Pre-treatment, 2nd week, 1st, 2nd, 3rd and 6th month after injection]

    Digital pain severity or paresthesia/dysthesia was evaluated using visual analog scale (VAS). Pain score scale ranged from 0 to 10, with 10 indicating the most severe pain.

  2. Change from baseline of cross-sectional area of the median nerve on 2nd week, 1st, 2nd, 3rd and 6th month after injection [Pre-treatment, 2nd week, 1st, 2nd, 3rd and 6th month after injection]

    Using the musculoskeletal sonogram to measure the cross-sectional area of the median nerve before treatment and multiple time frame after treatment.

  3. Change from baseline of conduction velocity, amplitude of median nerve on 2nd week, 1st, 2nd, 3rd and 6th month after injection [Pre-treatment, 2nd week, 1st, 2nd, 3rd and 6th month after injection]

    Electrophysiological study of the median nerve before treatment and multiple time frame after treatment.

  4. Change from baseline of finger pinch on 2nd week, 1st, 2nd, 3rd and 6th month after injection [Pre-treatment, 2nd week, 1st, 2nd, 3rd and 6th month after injection]

    The finger pinch strength was measured using dynamometer (Fabrication Enterprises Inc., USA). The subject was seated with shoulder adducted and neutrally rotated with the elbow flexed at 90°. The forearm and wrist were positioned in a neutral position for the palmar pinch

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age between 20-80 year-old.

  • Diagnosis was confirmed using an electrophysiological study

Exclusion Criteria:
  • Cancer

  • Coagulopathy

  • Pregnancy

  • Inflammation status

  • Cervical radiculopathy

  • Polyneuropathy, brachial plexopathy

  • Thoracic outlet syndrome

  • Previously undergone wrist surgery or steroid injection for CTS

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Physical Medicine and Rehabilitation, Tri-Service General Hospital Taipei Neihu District Taiwan 886

Sponsors and Collaborators

  • Tri-Service General Hospital

Investigators

  • Principal Investigator: Yung-Tsan Wu, MD, Department of Physical Medicine and Rehabilitation, Tri-Service General Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Yung-Tsan Wu, Attending Physician of Department of Physical Medicine and Rehabilitation, Tri-Service General Hospital
ClinicalTrials.gov Identifier:
NCT03031041
Other Study ID Numbers:
  • Difference PIT for CTS
First Posted:
Jan 25, 2017
Last Update Posted:
Oct 31, 2019
Last Verified:
Oct 1, 2019
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Yung-Tsan Wu, Attending Physician of Department of Physical Medicine and Rehabilitation, Tri-Service General Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 31, 2019